Please login to the form below

Not currently logged in
Email:
Password:

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Eli Lilly and Company has strengthened its oncology team with the addition of Kimberly Blackwell, who joins the pharma group as its new vice president of early phase development and immuno-oncology.

Blackwell currently serves as a professor of medicine and assistant professor of radiation oncology at Duke University Medical Center, and she is also the co-director of the Duke women’s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles.

Sue Mahon, senior vice president and president of Lilly Oncology, said: “We are pleased and honoured to welcome Dr Blackwell to Lilly, she is a highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory approvals.

“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”

15th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics